Concerning this topic, the efficacy of systemic administration of nanoparticles containing PKCε-repressive miRs in counteracting tumor growth and in conferring survival advantage have been already demonstrated in preclinical mouse models of Head and Neck Squamous Cell Carcinoma (HNSCC) [39]. The gene discussed is PRKCE; the disease is head and neck squamous cell carcinoma.